Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease.

Journal of neural transmission (Vienna, Austria : 1996) - 1 Sept 2010

Sala Gessica, Brighina Laura, Saracchi Enrico, Fermi Silvia, Riva Chiara, Carrozza Veronica, Pirovano Marta, Ferrarese Carlo

Abstract excerpt

Despite advances in neuroimaging, the diagnosis of idiopathic Parkinson's disease (PD) remains clinical. The identification of biological markers for an early diagnosis is of great interest to start a neuroprotective therapy aimed at slowing, blocking or reversing the disease progression. Vesicular monoamine transporter 2 (VMAT2) sequesters cytoplasmic dopamine into synaptic vesicles for storage and release....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Analysis of Variance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Platelets

Share to Blotting, Western

Share to Parkinson Disease

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to RNA, Messenger

Share to Vesicular Monoamine Transport Proteins

Source

Identifiers

PMID: 20665056
DOI: 10.1007/s00702-010-0446-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease.PMID 20665056Read ↗

Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.Semantic proximity Read ↗

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.Semantic proximity Read ↗

A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in plateletsSemantic proximity Read ↗

hVMAT2: A Target of Individualized Medication for Parkinson's Disease.Semantic proximity Read ↗

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditionsSemantic proximity Read ↗

Lack of association between polymorphic microsatellites of the VMAT2 gene and Parkinson's disease in Japan.Semantic proximity Read ↗

Mice with Very Low Expression of the Vesicular Monoamine Transporter 2 Gene Survive into Adulthood: Potential Mouse Model for ParkinsonismSemantic proximity Read ↗

Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individualsSemantic proximity Read ↗

Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's diseaseSemantic proximity Read ↗

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in womenSemantic proximity Read ↗

Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson’s diseaseSemantic proximity Read ↗

Cerebrospinal fluid synaptic proteins as useful biomarkers in tyrosine hydroxylase deficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.